ARDX Ardelyx, Inc.

14.75
0  -1%
Previous Close 14.95
Open 14.95
Price To book 3.66
Market Cap 698.07M
Shares 47,327,000
Volume 92,289
Short Ratio 4.24
Av. Daily Volume 230,969

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Onset of action trial data due 3Q 2017.
RDX7675
Hyperkalemia
Phase 3 trial initiation announced January 3, 2017.
RDX227675
Hyperkalemia
Phase 3 released February 15, 2017 - primary endpoint met. Second Phase 3 trial to be initiated mid-2017.
Tenapanor
Hyperphosphatemia in end-stage renal disease (ESRD) patients
Phase 3 data due 2Q and 2H 2017, respectively, in each of its two Phase 3 trials.
Tenapanor
Constipation-predominant irritable bowel syndrome (IBS-C)

Latest News

  1. ARDELYX, INC. Files SEC form 8-K, Other Events
  2. Adaptimmune Broadens Executive Team
  3. Adaptimmune Broadens Executive Team
  4. ARDELYX, INC. Files SEC form 8-K, Change in Directors or Principal Officers
  5. Ardelyx Announces Presentation at Cowen and Company 37th Annual Healthcare Conference
  6. ARDELYX, INC. Financials
  7. Wedbush Has A New Best Idea For 2017: Ardelyx
  8. Ardelyx, Inc. :ARDX-US: Earnings Analysis: Q4, 2016 By the Numbers
  9. ARDELYX, INC. Files SEC form 10-K, Annual Report
  10. Ardelyx reports 4Q loss
  11. Ardelyx reports 4Q loss
  12. Ardelyx Reports Clinical Progress and Fourth Quarter and Full Year 2016 Financial Results
  13. Blog Coverage Ardelyx Reports Positive Data for the Treatment for Hyperphosphatemia in Patients with End-Stage Renal disease
  14. Here’s What The Latest Ardelyx Inc (ARDX) Data Means For The Company Going Forward
  15. Ardelyx Says Tenapanor Did Well In Phase 3 Study
  16. Biotech Premarket Movers: Ardelyx, Acorda Therapeutics, Medicines Co.
  17. ARDELYX, INC. Files SEC form 8-K, Other Events
  18. Ardelyx Announces Successful Phase 3 Trial of Tenapanor for Hyperphosphatemia in Patients with End-Stage Renal Disease
  19. ARDELYX, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Regulation FD Disclosure, Financial
  20. Ardelyx Announces Initiation of Two Clinical Trials for RDX7675 for Treatment of Hyperkalemia